[{"id":"9f2ba0bc-1d5e-497d-abc6-0631298ff4a9","acronym":"CAPRICE","url":"https://clinicaltrials.gov/study/NCT05519670","created_at":"2022-08-29T13:03:12.666Z","updated_at":"2025-02-25T13:13:08.543Z","phase":"Phase 1b/2","brief_title":"A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr","source_id_and_acronym":"NCT05519670 - CAPRICE","lead_sponsor":"Institut Paoli-Calmettes","biomarkers":" HER-2 • CDK4 • BRCA","pipe":" | ","alterations":" HER-2 overexpression • HER-2 overexpression + HR negative","tags":["HER-2 • CDK4 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 overexpression + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Zejula (niraparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2022-08-29"}]